Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO MAP 2022 | TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx) (TRACERx)

Robert Hynds, PhD, UCL, London, UK, talks on the TRACERx (NCT01888601) study aiming to characterize tumor heterogeneity in a cohort of patients with non-small cell lung cancer (NSCLC). Dr Hynds provides an overview of his role in TRACERx involving the development of patient-derived xenograft (PDX) models derived from multiple regions of primary NSCLC from patients in lung TRACERx to assess the fidelity of PDX models as a surrogate for the patients’ tumor. https://www.biorxiv.org/content/10.1101/2023.01.06.521078v1.full. This interview took place at the Molecular Analysis for Precision oncology (MAP) Congress 2022 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.